Revised forecast
Fiscal year ending March 2026 · Full year (1 April 2025 to 31 March 2026)Previous forecast published 30 January 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Sales for the healthcare market are showing signs of recovery in Europe, North America and China, and year-end demand was captured in Japan, so net sales are expected to exceed the previous forecast. While a gain on the sale of investment securities of approximately ¥6,600 million will be recorded as extraordinary income, business restructuring costs and related expenses of approximately ¥450 million and impairment losses on property, plant and equipment of approximately ¥500 million are scheduled to be recorded.
Approximately ¥450 million in business restructuring costs and related expenses associated with restructuring the sales organization in Europe and reorganizing certain development and production sites, and approximately ¥500 million in impairment losses on property, plant and equipment at a European development and manufacturing company
| Item | Details |
|---|---|
| Net Sales | 79,000 Millions of yen → 81,300 Millions of yen（+2.9%） |
| Operating profit | 1,400 Millions of yen → 2,300 Millions of yen（+64.3%） |
| Ordinary income | 2,900 Millions of yen → 3,700 Millions of yen（+27.6%） |
| Profit attributable to owners of the parent | 3,200 Millions of yen → 7,300 Millions of yen（+128.1%） |
| Net income per share | 78.93 yen → 180.06 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year (1 April 2025 to 31 March 2026) |
| Publication date of previous forecast | 30 January 2026 |
| Previous-period results | Net Sales 80,493 Millions of yen / Operating profit 3,706 Millions of yen / Ordinary income 4,555 Millions of yen / Profit attributable to owners of the parent 4,148 Millions of yen / Net income per share 100.81 yen |
| Reason for the revision | Sales for the healthcare market are showing signs of recovery in Europe, North America and China, and year-end demand was captured in Japan, so net sales are expected to exceed the previous forecast. While a gain on the sale of investment securities of approximately ¥6,600 million will be recorded as extraordinary income, business restructuring costs and related expenses of approximately ¥450 million and impairment losses on property, plant and equipment of approximately ¥500 million are scheduled to be recorded. |
| Details and amount of extraordinary loss | Approximately ¥450 million in business restructuring costs and related expenses associated with restructuring the sales organization in Europe and reorganizing certain development and production sites, and approximately ¥500 million in impairment losses on property, plant and equipment at a European development and manufacturing company |
| Dividend forecast revision | No change (year-end dividend of ¥55.00) |
| Consolidated / non-consolidated | Consolidated |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales for the healthcare market are showing signs of recovery in Europe, North America and China, and year-end demand was captured in Japan, so net sales are expected to exceed the previous forecast. In addition, a gain on the sale of investment securities of approximately ¥6,600 million is expected to be recorded as extraordinary income, while business restructuring costs and impairment losses are also expected to be recorded.